14/09/2025
Check out Luke's Top Five from Episode 165! 🎧
➡Chronic hand eczema includes the subtypes: atopic dermatitis, allergic contact dermatitis, hyperkeratotic eczema, irritant contact dermatitis, and vesicular/dyshidrotic eczema.
➡Delgocitinib, the first topical pan–JAK inhibitor, was FDA-approved in July 2025 for chronic hand eczema. In an RCT of topical steroid-refractory patients, treatment success (IGA-CHE 0–1 at 16 weeks) was achieved in 25% on delgocitinib vs 9% on placebo.
➡Retinoids reduce scaling and are effective for some ichthyosis phenotypes (lamellar, PPK) but should be avoided in others such as Netherton syndrome. Retinoids are not a permanent solution, and symptoms recur after discontinuation.
➡Acitretin can persist in your system for up to 3 years due to its conversion to etretinate, which accumulates and gets stored in fat. Use caution in patients of childbearing potential.
➡Long-term, retinoids may cause skeletal toxicities, including premature epiphyseal closure, tendon/ligament calcifications, osteophytes, DISH (diffuse idiopathic skeletal hyperostosis), and altered bone density.